Project Grant HT9425261E240
- Federal Grant Award Summary Thomas Jefferson University, operating as Sidney Kimmel Medical College, received a $3.12 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025 through August 31, 2029. The award supports research and development activities focused on novel tumor-targeted immunotherapies against metastatic uveal melanoma. This research initiative will be conducted at the...
- Federal Grant Award Summary Thomas Jefferson University, operating as Sidney Kimmel Medical College, received a $624,000 Project Grant award dated July 15, 2025, from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). The award supports research to identify mechanisms of tolerance and resistance to darovasertib plus crizotinib in uveal melanoma, with a performance period extending through July 14, 2027. This research addresses critical...
- Federal Grant Award Summary Thomas Jefferson University, operating as Sidney Kimmel Medical College, received a $1,998,484 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2026, through August 31, 2029. The award funds biomedical research titled "Deciphering the Role of PIK3CA Mutations in Tumorigenesis of HER2-Positive Breast Cancer," with research activities conducted at the...
- Federal Project Grant Award Summary Thomas Jefferson University, operating as Sidney Kimmel Medical College, received a $560,000 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective August 1, 2026, through July 31, 2028. The award supports research titled "Novel Way to Target B-Cell Lymphomas to Reduce Relapse/Refractory Disease," which investigates innovative therapeutic approaches to improve...
- Federal Project Grant Award Summary Thomas Jefferson University, operating as Sidney Kimmel Medical College, received a $1.1 million Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective June 1, 2026, through May 31, 2030. The project, titled "Chemoradiation Imparts KRAS-Mediated Resistance to Immunotherapy in Non-Small Cell Lung Cancer," supports basic and applied biomedical research addressing Service...
- This federal Project Grant award of $858,000.00 from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program supports a longitudinal analysis of the mesenchymal cell state from melanoma initiation to metastatic progression at Thomas Jefferson University's Sidney Kimmel Medical College. The award, effective August 1, 2024, with a completion date of July 31, 2027, funds advanced biomedical research aimed at transforming healthcare for...
- Federal Grant Award Summary Thomas Jefferson University, operating as Sidney Kimmel Medical College, received a $819,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective May 1, 2025, with a completion date of April 30, 2028. The award funds research investigating chromium (VI)-driven profibrotic microenvironment and its contribution to lung carcinogenesis, addressing a critical occupational and environmental...
- The Defense Health Agency awarded a $756,897 Project Grant to Thomas Jefferson University, doing business as the Sidney Kimmel Medical College, for the federal grant program "Military Medical Research and Development" (CFDA 12.420). The grant, effective August 1, 2024 through July 31, 2027, will support "Second-Generation Precision Medicine for BRCA-Mutant Ovarian Cancer" research. Thomas Jefferson University, a leading academic medical center known for its innovative medical...
- Thomas Jefferson University, doing business as Sidney Kimmel Medical College, was awarded a $234,000 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program. The three-year grant will fund research into precision therapies for metastatic uveal melanoma prevention and treatment by investigating multimodal GNAQ signaling pathways. Through September 2021 to August 2024, Sidney Kimmel Medical College researchers will work to transform...
- The U.S. Department of Defense's Defense Health Agency awarded a $780,000 Project Grant to Thomas Jefferson University, doing business as Sidney Kimmel Medical College, for a 3-year research project titled "DEGRADATION OF MUTANT GNAQ 11 IN UVEAL MELANOMA CELLS". The grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research related to military medicine, including cancer, neurological disorders, and other conditions...
Thomas Jefferson University (operating as Sidney Kimmel Medical College) received a $1.35 million Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2026, through August 31, 2030. This four-year award supports identification and evaluation of immune and targeted therapies for acral melanoma, a rare form of melanoma affecting the military and general populations. The research will be conducted at the institution's Philadelphia, Pennsylvania facility and leverages the Sidney Kimmel Cancer Center's existing research infrastructure and expertise in cancer biology. The project represents a component of the Defense Health Agency's broader portfolio of investigator-initiated biomedical research addressing conditions affecting Service Members and the American public. This award aligns with the agency's mission to support basic, applied, and advanced research that transforms health care outcomes through innovative therapeutic approaches. Thomas Jefferson University's cancer research capabilities, including its NCI-designated comprehensive cancer center designation and existing melanoma research programs, position the institution as a capable recipient for developing and evaluating novel treatment modalities in this clinical area.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.3m | 5/26/26 |